Last reviewed · How we verify

Azienda Ospedaliero-Universitaria di Modena — Portfolio Competitive Intelligence Brief

Azienda Ospedaliero-Universitaria di Modena pipeline: 3 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

3 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Recombinant LH (Luveris) Recombinant LH (Luveris) marketed Gonadotropin; recombinant hormone Luteinizing hormone receptor (LHCGR) Reproductive endocrinology; Fertility
Pain killer Pain killer marketed
peritoneal dialysate at 37°C temperature peritoneal dialysate at 37°C temperature marketed Renal replacement therapy solution Nephrology
No Treatment Added No Treatment Added phase 3

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Instituto de Investigacion Sanitaria La Fe · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Azienda Ospedaliero-Universitaria di Modena:

Cite this brief

Drug Landscape (2026). Azienda Ospedaliero-Universitaria di Modena — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/azienda-ospedaliero-universitaria-di-modena. Accessed 2026-05-17.

Related